Neil F. McFarlane - 10 Oct 2026 Form 4 Insider Report for ZEVRA THERAPEUTICS, INC. (ZVRA)

Reporting relationship: President and CEO, Director
Issuer ticker: ZVRA
Reported as of: 10 Oct 2026
Net transaction value: -$224,948
SEC form: 4
Accepted by SEC: 13 Oct 2026, 16:24:28 UTC
Prior SEC filing: 10 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Timothy J. Sangiovanni, Attorney-in-Fact for Neil F. McFarlane

Filing notes and source

Key filing fact

Neil F. McFarlane filed Form 4 for ZEVRA THERAPEUTICS, INC. (ZVRA) on 13 Oct 2026.

Key facts

This page summarizes Neil F. McFarlane's Form 4 filing for ZEVRA THERAPEUTICS, INC. (ZVRA).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 13 Oct 2026, 16:24.

Change

Previous filing in this sequence was filed on 10 Feb 2026.
Current net transaction value: -$224,948.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001681098 Primary reporting owner

McFarlane Neil F.

Relationship: President and CEO, Director
Address: C/O ZEVRA THERAPEUTICS, INC., 101 FEDERAL STREET, BOSTON
Signature: /s/ Timothy J. Sangiovanni, Attorney-in-Fact for Neil F. McFarlane
Signature date: 13 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ZVRA transaction

Common Stock

Options Exercise

Transaction value
Shares: +50,000
Change %: +13%
Price
Shares after: 437,225
Date: 10 Oct 2026
Ownership: Direct
Footnotes: F1

ZVRA transaction

Common Stock

Sale

Transaction value: -$224,948
Shares: -20,000
Change %: -4.6%
Price: $11.25
Shares after: 417,225
Date: 12 Oct 2026
Ownership: Direct
Footnotes: F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ZVRA transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value
Shares: -50,000
Change %: -50%
Price: $0.000000^*
Shares after: 50,000
Date: 10 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price: $0.000000
Footnotes: F1, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

Footnote F2

Adoption date of referenced 10b5-1(c) plan is: 03-25-2026

Footnote F3

This transaction was executed in multiple trades at prices ranging from $11.07 to $11.36. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Footnote F4

25% of the RSUs vested and settled on each of October 10, 2024, October 10, 2025 and October 10, 2026. The remaining 25% of the shares will vest on 10/10/2027, provided that at the relevant vesting date the Reporting Person's employment relationship has not been terminated as defined in the Issuer's 2023 Employment Inducement Award Plan. All shares will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason.